These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib. Martini DJ; Kline MR; Liu Y; Shabto JM; Carthon BC; Russler GA; Yantorni L; Hitron EE; Caulfield S; Goldman JM; Harris WB; Kucuk O; Master VA; Bilen MA Cancer Treat Res Commun; 2021; 28():100393. PubMed ID: 34029879 [TBL] [Abstract][Full Text] [Related]
9. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410 [TBL] [Abstract][Full Text] [Related]
10. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic. Richter I; Poprach A; Zemánková A; Büchler T; Bartoš J; Šámal V; Študentová H; Rozsypalová A; Dvořák J; Brom O; Melichar B Klin Onkol; 2021; 34(5):392-400. PubMed ID: 34915708 [TBL] [Abstract][Full Text] [Related]
11. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824 [TBL] [Abstract][Full Text] [Related]
12. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ; Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544 [TBL] [Abstract][Full Text] [Related]
13. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. Escudier B; Powles T; Motzer RJ; Olencki T; Arén Frontera O; Oudard S; Rolland F; Tomczak P; Castellano D; Appleman LJ; Drabkin H; Vaena D; Milwee S; Youkstetter J; Lougheed JC; Bracarda S; Choueiri TK J Clin Oncol; 2018 Mar; 36(8):765-772. PubMed ID: 29309249 [TBL] [Abstract][Full Text] [Related]
14. Cabozantinib use in metastatic renal cell carcinoma patients in clinical practice: Evaluation of dosing patterns, tolerability, and outcomes compared to clinical trials. McElwee JH; Gourdin TS; Mikoll J; Weeda E; Sion AM J Oncol Pharm Pract; 2020 Jun; 26(4):861-865. PubMed ID: 31566113 [TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7). Santini D; Stellato M; De Giorgi U; Pantano F; De Lisi D; Casadei C; Maruzzo M; Bimbatti D; Naglieri E; Buti S; Bersanelli M; De Vivo R; Di Lorenzo G; Sbrana A; Verzoni E; Soraru' M; Fornarini G; Mucciarini C; Grillone F; Mini E; Vignani F; Attademo L; Pignata S; Procopio G Am J Clin Oncol; 2021 Mar; 44(3):121-125. PubMed ID: 33617179 [TBL] [Abstract][Full Text] [Related]
17. Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program. Albiges L; Fléchon A; Chevreau C; Topart D; Gravis G; Oudard S; Tourani JM; Geoffrois L; Meriaux E; Thiery-Vuillemin A; Barthélémy P; Ladoire S; Laguerre B; Perrot V; Billard A; Escudier B; Gross-Goupil M Eur J Cancer; 2021 Jan; 142():102-111. PubMed ID: 33253997 [TBL] [Abstract][Full Text] [Related]
18. Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study). Procopio G; Sepe P; Claps M; Buti S; Colecchia M; Giannatempo P; Guadalupi V; Mariani L; Lalli L; Fucà G; de Braud F; Verzoni E JAMA Oncol; 2022 Jun; 8(6):910-913. PubMed ID: 35420628 [TBL] [Abstract][Full Text] [Related]
19. The correlation between the incidence of adverse events and progression-free survival in patients treated with cabozantinib for metastatic renal cell carcinoma (mRCC). Kucharz J; Dumnicka P; Kusnierz-Cabala B; Demkow T; Wiechno P Med Oncol; 2019 Jan; 36(2):19. PubMed ID: 30666498 [TBL] [Abstract][Full Text] [Related]
20. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]